Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
Des. 2006 · John Wiley & Sons
E-boek
391
Bladsye
reportGraderings en resensies word nie geverifieer nie. Kom meer te wete
Meer oor hierdie e-boek
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
Meer oor die skrywer
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Gradeer hierdie e-boek
Sê vir ons wat jy dink.
Lees inligting
Slimfone en tablette
Installeer die Google Play Boeke-app vir Android en iPad/iPhone. Dit sinkroniseer outomaties met jou rekening en maak dit vir jou moontlik om aanlyn of vanlyn te lees waar jy ook al is.
Skootrekenaars en rekenaars
Jy kan jou rekenaar se webblaaier gebruik om na oudioboeke wat jy op Google Play gekoop het, te luister.
E-lesers en ander toestelle
Om op e-inktoestelle soos Kobo-e-lesers te lees, moet jy ’n lêer aflaai en dit na jou toestel toe oordra. Volg die gedetailleerde hulpsentrumaanwysings om die lêers na ondersteunde e-lesers toe oor te dra.
